-- The expansion specifically targets technical bottlenecks in the cultivation and functional validation of two high-value strains: Faecalibacterium prausnitzii and Akkermansia muciniphila.
Advancing Clinical Translation of Key Commensal Bacteria
Unlike traditional probiotics, Next-Generation Probiotics (NGPs) are characterized by their specific therapeutic potential for complex diseases. Creative Biolabs provides integrated solutions to transform these "star strains" into regulated medical products.
Targeting Inflammation with Faecalibacterium prausnitzii: As a major producer of butyrate, this strain is a primary candidate for treating Crohn's disease and ulcerative colitis. Creative Biolabs' platform addresses the extreme oxygen sensitivity of F. prausnitzii, providing specialized anaerobic fermentation and bioactivity assays to ensure metabolic potency.
Metabolic Regulation via Akkermansia muciniphila: Known for its role in maintaining the gut mucosal barrier, A. muciniphila is at the forefront of research into obesity, type 2 diabetes, and cancer immunotherapy (PD-1/PD-L1) enhancement. The company offers precise quantification and efficacy testing to support its pharmaceutical application.
Expert Insight: From Commensal Microbes to Live Biotherapeutics
"The industry is moving past general gut health toward targeted microbial drugs," stated a project lead at Creative Biolabs. "The difficulty lies in the transition from a laboratory isolate to a stable, scalable drug product. By optimizing the discovery pipeline for F. prausnitzii and A. muciniphila, we are helping our clients bridge the gap between microbiome signatures and clinical outcomes."
Technical Framework: The LBP Development Pipeline
Creative Biolabs utilizes a structured methodology to ensure that Live Biotherapeutic Products (LBPs) meet international regulatory expectations.
Isolation & Identification: Utilizing metagenomic tools for strain-level precision.
Safety Profiling: Screening for antibiotic resistance genes (ARGs) and virulence factors to ensure non-pathogenicity.
Functional Assays: Evaluating immune-modulatory effects using co-culture systems and germ-free animal models.
Process Development: Solving the stability challenges of live bacteria through proprietary lyophilization and encapsulation technologies.
Technical Background: Solving NGP Challenges (FAQ)
A frequent challenge in NGP development is the strict anaerobiosis required for many beneficial gut bacteria. Traditional manufacturing often fails to maintain high viability. Creative Biolabs addresses this by employing advanced anaerobic workstations and protective agents during the freeze-drying process. Additionally, for strains like A. muciniphila, the platform monitors the specific interaction between the bacteria and the host's mucus layer to ensure the intended therapeutic mechanism—restoring rather than degrading the gut barrier—is preserved.
About
Creative Biolabs is a leading biotech service provider with decades of experience in drug discovery. Its microbiome division is dedicated to providing high-quality research tools and contract services for the global biopharmaceutical industry, focusing on the therapeutic potential of the human microbiota.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://live-biotherapeutic.creative-biolabs.com
Release ID: 89185754
Google
RSS